Loading…
← CockpitCompetitor Analysis › AKUMS.NS Akums Drugs and Pharmaceuticals LimitedOpen in the cockpit ↗

Akums Drugs and Pharmaceuticals LimitedAKUMS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Biotechnology

India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.

Momentum strong 76
Mkt cap
$1.21B
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$2.25M
20-day average traded
Fwd P/E
25.6×
forward earnings
ROIC−WACC
+5.5 pp
WACC 13.5%
Hurdle
+5 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹716.15
1D-0.1%
1W-7.0%
1M+0.9%
3M-3.8%
6M+37.8%
YTD+58.0%
1Y+58.0%
ATR %3.8%
Beta0.81
52w lowhigh14.6% off high

What Akums Drugs and Pharmaceuticals does

India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.

Makes formulations, finished tablets, injections and softgels, to the specifications of other drug companies, which sell them under their own labels, so income is contract-manufacturing fees spread across many customers rather than one product. It listed on the stock market in 2024.

Products and services

  • Contract manufacturing (formulations)
  • Own branded generics
  • API manufacturing

Customers

  • Domestic and global pharma companies (outsourcing
  • Retail pharmacy channel (own brands)

Where it sits in the supply chain

  • Pharmaceuticals
  • Contract development & manufacturing…
  • Own-brand generic formulations

What could go right

  • Pharma outsourcing/CDMO demand growth
  • Own-brand generics expansion

What could go wrong

  • Customer concentration among outsourcing pharma clients
  • Regulatory/plant-approval risk

Moat: narrow (scale, regulatory licence, process know-how). Largest-scale, multi-approval manufacturing base in India's CDMO market, though the space has several capable rivals.

Headquarters: Haridwar, India · Founded: 2004 · Employees: 18,010

Named competitors

  • Windlas Biotech private or unlisted
  • Suven Pharma private or unlisted
  • Divi's Laboratories DIVISLAB.NS

Akums Drugs and Pharmaceuticals at a glance

Size Akums Drugs and Pharmaceuticals (AKUMS.NS) is an India Health Care company (Biotechnology) with a market value of $1.21B, the 552nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹716.15 on 18 Nov 2026.

Performance Over six months the shares gained 37.8%, against -20.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median -1.6%); the operating margin is 10.4% (peer median -71.3%).

Valuation It trades at 25.6× forward earnings against a peer median of 41.3× (cheapest of 7).

Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.5 points above its cost of capital (13.5% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026AKUMS.NS 139Peer median 77
Six months, rebased to 100: Akums Drugs and Pharmaceuticals against the median of its 20 peers (local-currency closes).

Akums Drugs and Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹48.3B₹43.6B₹41.2B₹41.8B₹36.5B
Revenue growth—+6%-1%+14%—
Gross profit₹11.0B₹6.85B₹5.91B₹6.27B₹4.57B
EBITDA₹6.68B₹5.26B₹4.63B₹4.85B₹3.09B
Net income₹3.64B₹2.55B₹3.38B-₹40.4M₹949M
Free cash flown/a₹9.80B₹1.90B₹1.55B-₹1.85B
Capital expendituren/a₹2.31B₹2.72B₹3.11B₹3.29B
Total debt₹1.17B₹1.57B₹882M₹5.65B₹6.19B

Quarterly statements and history in the cockpit →

Akums Drugs and Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%MLYS688739000403301207CMPSNVAXVORNUVBTYRAJBIO96064588002030AKUMS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Akums Drugs and Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%50×100×688739000403301207NVAX6185300482AKUMS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Akums Drugs and Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%688739301207002030300482AKUMS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Akums Drugs and Pharmaceuticals is the large dot.

Akums Drugs and Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AKUMS.NS vs DIVISLAB.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Akums Drugs and Pharmaceuticals AKUMS.NS$1.21B+38%+18%10%25.6×15.3%
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%

How Akums Drugs and Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Akums Drugs and Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAKUMS.NSPeer medianRank in peer set
1-month return+0.9%-12.5%3rd highest of 21
6-month return+37.8%-20.5%2nd highest of 19
Distance from 52-week high-14.6%-48.0%2nd highest of 21
Revenue growth (TTM)+17.5%-1.6%6th highest of 15
Operating margin10.4%-71.3%highest of 15
Forward P/E25.6×41.3×cheapest of 7
Growth the price implies (Req g, 7 yrs)15.3%10.5%2nd most demanding of 5
Growth delivered (Del g)+9.9%-10.0%highest of 5
Hurdle (Req g minus delivered)+5.5 pp+28.6 ppleast demanding of 5
ROIC minus cost of capital+5.5 pp-8.7 pphighest of 10
EV / EBITDA14.6×n/a—
Net debt / EBITDA-2.3×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%25.6×15.3%+9.9%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%44.0×6.6%-7.0%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%26.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Daan Gene 002030.SZChina$1.05B-17%+1%-81%n/a4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%28.4×14.3%-5.8%

Questions

Who are Akums Drugs and Pharmaceuticals's main competitors?
Named competitors: Windlas Biotech (private or unlisted), Suven Pharma (private or unlisted), Divi's Laboratories (DIVISLAB.NS). The cockpit's measured peer set (industry) also includes Mineralys Therapeutics (MLYS), Liaoning Chengda Biotechnology (688739.SS), Pacific Shuanglin Bio-pharmacy (000403.SZ), Hualan Biological Vaccine (301207.SZ), Kardigan (KARD), COMPASS Pathways Plc Sponsored ADR (CMPS).
Is Akums Drugs and Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 25.6× against a peer median of 41.3×, cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Akums Drugs and Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +37.8% against -20.5% for the median peer; over one year +58.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.